

VOPRAZAN®

Vonoprazan 10 mg and 20 mg



Category

Potassium-Competitive Acid Blocker (PCAB)



Dosage Forms

10 and 20 mg tablets



Indications

- Relief of heartburn (GERD¹)
- Healing of erosive esophagitis
- As part of a multidrug regimen for *H. pylori*² eradication



Why PCAB?

- A new-generation acid suppression option
- Full effect achieved with the first dose
- Convenient once-daily dosing for GERD and esophagitis
- Rapid onset of action and longer acid suppression than PPIs
- Convenient dosing regardless of food intake, unlike PPIs
- Higher eradication rate of *H. pylori* than PPI-based therapies
- Effective even in PPI-resistant severe reflux disease



Pregnancy

Human data are insufficient to identify drug-associated risks during pregnancy.



Breastfeeding

Vonoprazan is present in human milk. The decision to breastfeed during therapy should consider the risks and benefits for mother and infant.

¹Gastroesophageal Reflux Disease

²*Helicobacter pylori*

VOPRAZAN®

Vonoprazan 10 mg and 20 mg

Dosing

VOPRAZAN®
Vonoprazan 20 mg

Treatment of erosive esophagitis
20 mg once daily
(8 weeks)

VOPRAZAN®
Vonoprazan 20 mg

H. pylori eradication
20 mg twice daily
(In combination with antibiotics
for 14 days)

VOPRAZAN®
Vonoprazan 10 mg

**Maintenance treatment of erosive
esophagitis**
10 mg once daily
(Up to 6 months)

VOPRAZAN®
Vonoprazan 10 mg

**GERD associated with nonerosive
esophagitis**
10 mg once daily
(4 to 8 weeks)



کد بیمه تامین اجتماعی: ۷۴۱۰۵۵

کد بیمه سلامت: ۲۸۲۳۷۴



کد بیمه تامین اجتماعی: ۷۴۱۰۸۰

کد بیمه سلامت: ۳۱۳۵۴۶



Orchid Pharmed
Sky's the Limit



Arvand Pharmed

References

